Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2020 2
2021 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yuan hui yang (2 results)?
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Chen GL, Qiu YZ, Wu KQ, Wu Y, Wang YH, Zou YY, Peng CG, Zhao J, Su C, Ma JH, Ni SN, Wang X, Jin TH, Jiang Q, Guo T, Xu Y, Huang CC, Zhang Q, Liu KL, Ji L, Yang HY, Li CL, Su YW, Lu X, Li LJ. Chen GL, et al. Among authors: wang yh. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285089. doi: 10.1080/21645515.2023.2285089. Epub 2023 Dec 18. Hum Vaccin Immunother. 2023. PMID: 38111106 Free PMC article. Clinical Trial.
Open reduction and locked compression plate fixation, with or without allograft strut, for periprosthetic fractures in patients who had a well-fixed femoral stem: a retrospective study with an average 2-year follow-up.
Lv H, Guo X, Wang YH, Zhang ZJ, Zou LF, Xue H, Huang DH, Tan MY. Lv H, et al. Among authors: wang yh. BMC Musculoskelet Disord. 2022 Jan 19;23(1):69. doi: 10.1186/s12891-022-05008-2. BMC Musculoskelet Disord. 2022. PMID: 35045862 Free PMC article.
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
Jin F, Qiu Y, Wu Z, Wang YH, Cai C, Fu L, Jiao W, Wang H, Gao M, Su C, Ma JH, Xu Y, Huang CC, Zhang Q, Ni S, Zhao M, Guo L, Ji L, Yang H, Zhao Y, Li C, Lu X, Su YW, Li Q. Jin F, et al. Among authors: wang yh. Vaccine. 2024 Mar 7;42(7):1561-1570. doi: 10.1016/j.vaccine.2024.01.098. Epub 2024 Feb 15. Vaccine. 2024. PMID: 38365485 Clinical Trial.
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
Su YW, Qiu YZ, Wang YH, Xu Y, Huang CC, Zhang Q, Su C, Ma JH, Liu W, Liu Y, Zhao MS, Yang HY, Li CL, Lu X. Su YW, et al. Among authors: wang yh. Vaccine. 2024 Apr 2;42(9):2438-2447. doi: 10.1016/j.vaccine.2024.03.005. Epub 2024 Mar 8. Vaccine. 2024. PMID: 38461050 Clinical Trial.